Monte Rosa Therapeutics, Inc. (GLUE)
13.78
-0.52
(-3.67%)
USD |
NASDAQ |
Aug 24, 16:00
13.77
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Max Drawdown (5Y) : 94.08% for July 31, 2026
Max Drawdown (5Y) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| July 31, 2026 | 94.08% |
| June 30, 2026 | 94.08% |
| May 31, 2026 | 94.08% |
| April 30, 2026 | 94.08% |
| March 31, 2026 | 94.08% |
| February 28, 2026 | 94.08% |
| January 31, 2026 | 94.08% |
| Date | Value |
|---|---|
| December 31, 2025 | 94.08% |
| November 30, 2025 | 94.08% |
| October 31, 2025 | 94.08% |
| September 30, 2025 | 94.08% |
| August 31, 2025 | 94.08% |
| July 31, 2025 | 94.08% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Nurix Therapeutics, Inc. | 91.53% |
| Gilead Sciences, Inc. | 26.58% |
| Ironwood Pharmaceuticals, Inc. | 96.33% |
| Capricor Therapeutics, Inc. | 91.80% |
| Cue Biopharma, Inc. | 99.01% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -25.86 |
| Beta (5Y) | 1.587 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 99.31% |
| Historical Sharpe Ratio (5Y) | -0.1133 |
| Historical Sortino (5Y) | -0.2748 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 33.01% |